登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>IL-31 RA / OSMR >CHEK-ATF094

Human IL-31 RA/OSMR (Luc) HEK293 Reporter Cell

For research use only.

描述(Description)

The Human IL-31 RA/OSMR (Luc) HEK293 Reporter Cell was engineered to express STAT3 signaling response element, but also express the receptors full length human IL-31 RA (Gene ID: 133396) and OSMR (Gene ID: 9180). When stimulated with human IL-31 protein, the IL-31/IL-31 RA interaction drives STAT3-mediated luminescence. Neutralization of biological effect of human IL-31 protein by corresponding antibody results in a decrease in luminescence.

应用说明(Application)

• Screen for neutralizing antibodies blocking the stimulation of human IL-31 protein.

IL-31 RA / OSMR Assay Principles

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (2 μg/mL) + Hygromycin (40 μg/mL) + Zeocin (20μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

Serum-free cell cryopreservation medium

装量(Quantity)

1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

IL-31 RA / OSMR FACS

Co-expression analysis of human IL-31 RA and OSMR on Human IL-31 RA/OSMR (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human IL-31 RA/OSMR (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human IL-31 RA antibody and APC-labeled anti-human OSMR antibody.

Protocol

 

Application

IL-31 RA / OSMR APPLICATION

Inhibition of human IL-31 protein-induced reporter activity by anti-human IL-31 RA neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-31 protein (Cat. No. IL1-H5247) with a final concentration of 0.001 μg/mL. The EC50 of anti-human IL-31 RA neutralizing antibody is approximately 0.609 μg/mL.

Protocol

IL-31 RA / OSMR APPLICATION

Inhibition of human IL-31 protein-induced reporter activity by anti-human OSMR neutralizing antibody.
This reporter cell was incubated with serial dilutions of antibodies in the presence of human IL-31 protein (Cat. No. IL1-H5247) with a final concentration of 0.001 μg/mL. The EC50 of anti-human OSMR neutralizing antibody is approximately 0.727 μg/mL.

Protocol

 

Signaling Bioassay

IL-31 RA / OSMR SIGNALING

Response to human IL-31 protein (RLU).
The Human IL-31 RA/OSMR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-31 protein (Cat. No. IL1-H5247). The EC50 was approximately 0.0102 μg/mL.

Protocol

IL-31 RA / OSMR SIGNALING

Response to human IL-31 protein (FOLD).
The Human IL-31 RA/OSMR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-31 protein (Cat. No. IL1-H5247). The max induction fold was approximately 328.

Protocol

 

Passage Stability

IL-31 RA / OSMR PASSAGE

Passage stability analysis by Signaling Bioassay.
The continuously growing Human IL-31 RA/OSMR (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human IL-31 protein. Human IL-31 protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 9-20.

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

Interleukin-31 receptor subunit alpha is a protein that in humans is encoded by the IL31RA gene, also known as IL-31 receptor subunit alpha, IL-31RA, GLM-R, Gp130-like receptor, CRL3, GPL. Oncostatin M receptor (OSMR) and IL31RA form the heterodimeric receptor through which IL31 signals. IL31RA is a strong activator of STAT3 and STAT5, whereas STAT1 is only marginally tyrosine-phosphorylated. dditionally, demonstrate Jak1 binding to GPL and its activation in heteromeric complexes with the OSMR beta but also in a homomeric receptor complex.

 

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定